Calcitonin gene-related peptide (CGRP) is a neuropeptide with potent vasodilatory effect, closely associated with migraine attacks. CGRP and its receptor (CGRP-R) are currently the most promising targets for the treatment and prevention of migraine. The migraine treatment drugs for CGRP mainly include CGRP-R antagonists and CGRP monoclonal antibodies. By blocking the binding of CGRP to its receptor, CGRP-R antagonists can have a similar effect on migraine as triptans, with a lower incidence of adverse reactions. They are more effective and safe new drugs for treating migraine. The author used the incoPat database to search and count the patent applications of small molecule CGRP/CGRP-R antagonists, analyzed the overall trend of patent applications, geographical distribution, applications of important applicants, the distribution of technical fields of patent applications, and the core patents of key varieties, and tried to reflect the patent application status of small molecule CGRP/CGRP-R antagonists, reveal their development trend, and give relevant suggestions. It provides a reference for domestic pharmaceutical companies and research institutions.